BioLineRx (NASDAQ:BLRX) Issues Earnings Results, Misses Estimates By $0.62 EPS

BioLineRx (NASDAQ:BLRX) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.62), Zacks reports. The business had revenue of $0.29 million during the quarter, compared to analysts’ expectations of $0.50 million. BioLineRx had a negative net margin of 563.70% and a negative return on equity of 37.73%.

BioLineRx Price Performance

BLRX stock opened at $2.60 on Monday. BioLineRx has a one year low of $2.15 and a one year high of $4.56. The firm has a market cap of $11.36 million, a PE ratio of -1.35 and a beta of 1.54. The firm’s 50 day moving average price is $2.92 and its 200-day moving average price is $2.84. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.43 and a current ratio of 1.58.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioLineRx in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, BioLineRx presently has a consensus rating of “Sell”.

About BioLineRx

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.